These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 9856962

  • 21. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Jan 03; 113(1):67-73. PubMed ID: 16365195
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group.
    Lancet; 2002 Mar 23; 359(9311):995-1003. PubMed ID: 11937178
    [Abstract] [Full Text] [Related]

  • 23. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M, REGAAL Study Investigators.
    J Hypertens; 2002 Sep 23; 20(9):1855-64. PubMed ID: 12195129
    [Abstract] [Full Text] [Related]

  • 24. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC.
    J Hum Hypertens; 2004 Jun 23; 18(6):367-73. PubMed ID: 15029217
    [Abstract] [Full Text] [Related]

  • 25. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec 23; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 26. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM, LIFE Study Investigators.
    Am Heart J; 2003 May 23; 145(5):919-25. PubMed ID: 12766755
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group.
    Lancet; 2002 Mar 23; 359(9311):1004-10. PubMed ID: 11937179
    [Abstract] [Full Text] [Related]

  • 28. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, LIFE Study Investigators.
    Ann Intern Med; 2007 Sep 04; 147(5):311-9. PubMed ID: 17785486
    [Abstract] [Full Text] [Related]

  • 29. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Hypertension; 2007 Nov 04; 50(5):984-90. PubMed ID: 17893425
    [Abstract] [Full Text] [Related]

  • 30. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC, Westergaard B, Sehestedt T, Kjeldsen SE, Lindholm LH, Wachtell K, Devereux RB, Ibsen H, Nieminen MS, Dahlöf B, Olsen MH.
    J Hypertens; 2012 Jun 04; 30(6):1252-9. PubMed ID: 22499288
    [Abstract] [Full Text] [Related]

  • 31. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
    Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Blood Press; 2009 Jun 04; 18(6):348-61. PubMed ID: 20001655
    [Abstract] [Full Text] [Related]

  • 32. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlöf B.
    Am J Hypertens; 2001 Aug 04; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [Abstract] [Full Text] [Related]

  • 33. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K.
    Circulation; 2007 Aug 14; 116(7):700-5. PubMed ID: 17664372
    [Abstract] [Full Text] [Related]

  • 34. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
    Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, Aalto T, Gerdts E, Devereux RB.
    Circulation; 2002 Mar 05; 105(9):1071-6. PubMed ID: 11877357
    [Abstract] [Full Text] [Related]

  • 35. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B.
    Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333
    [Abstract] [Full Text] [Related]

  • 36. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.
    J Hypertens; 2014 Dec 01; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [Abstract] [Full Text] [Related]

  • 37. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Dahlöf B, Kjeldsen SE, Wachtell K.
    Hypertension; 2012 Aug 01; 60(2):347-53. PubMed ID: 22753219
    [Abstract] [Full Text] [Related]

  • 38. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
    Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, LIFE study group.
    J Hypertens; 2002 Sep 01; 20(9):1879-86. PubMed ID: 12195132
    [Abstract] [Full Text] [Related]

  • 39. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K, Dahlöf B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB.
    Am Heart J; 2002 Dec 01; 144(6):1057-64. PubMed ID: 12486431
    [Abstract] [Full Text] [Related]

  • 40. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B, LIFE Study Group.
    J Hypertens; 2005 Jul 01; 23(7):1425-31. PubMed ID: 15942467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.